Patient case (clinical description): A 67-year-old woman comes to the clinic due to recent episode of choking, dysphagia, and cough.  Her other medical problems include hypertension, dyslipidemia, and osteoarthritis.  She does not smoke or use alcohol. She lives with her husband and she is able to do her own daily activities. She used to teach elementary school. Blood pressure is 135/80 mm Hg.  The patient's breath smells bad. Other physical examinations are normal.  A barium swallow study reveals an abnormality in the upper esophagus with an outpouching at the junction of the lower part of the throat and the upper portion of the esophagus.

Patient's own account: I'm a 67-year-old lady, and I went to the clinic due to nonstop choking, difficulty swallowing, and coughing. I also suffer from hypertension, cholesterol, and osteoarthritis. I do not smoke or drink alcohol. I live with my husband, and we are independent retired elementary school teachers. During the exam, my blood pressure was 135/80 mm Hg. The doctor told me I had a smelly breath. How embarrassing! The rest of my physical exam was normal. I did a barium swallow test, which is an X-ray of my throat, which revealed a problem in the upper part of my esophagus, where there's a small pouch or bulge at the spot where my throat meets the esophagus.

Clinical trial: The WATS3D (Wide Area Transepithelial Sample Biopsy With 3-Dimensional Computer-Assisted Analysis) U.S. Registry

Eligibility criteria:
Inclusion Criteria:

          -  English speaking

          -  Able to read, comprehend, and complete the consent form

          -  Aged 18 to 80, and,

          -  Meet one of the following:

          -  Patients with heartburn or regurgitation undergoing a screening EGD, who undergo
             WATS3D sampling and forceps biopsies for suspicion of BE, or

          -  Patients with known BE with or without dysplasia undergoing a surveillance EGD with
             WATS3D biopsies and forceps biopsies, or

          -  Patients who have undergone endoscopic eradication therapy(including, but not limited
             to endoscopic mucosal resection, endoscopic submucosal dissection, radiofrequency
             ablation and/orcryoablation/spray cryotherapy)who are undergoing surveillance EGD
             following the establishment of complete eradication of intestinal metaplasia (CEIM)
             with accompanying WATS3D sampling and forceps biopsies.

        Exclusion Criteria:

          -  Patients meeting any of the following criteria will be excluded from this study:

          -  Patients who on their enrollment endoscopy have a visible highly suspicious lesion,
             such as a nodule or ulcer, (noted while undergoing endoscopy) that requires targeted
             biopsy will be excluded from the study.Patients requiring a targeted biopsy on
             follow-up endoscopies will be allowed to remain in the study.

          -  Patients who do not undergo both biopsy forceps and WATS3D biopsy of the esophagus on
             their initial evaluationfor routine care will be excluded from this study. Subsequent
             endoscopicevaluation may include forceps biopsies alone, WATS3D biopsies alone, or
             both forceps and WATS3D biopsies.
No condition on gender to be admitted to the trial.
No healthy subjects accepted to join the trial.
Subject must be at least 18 Years old.
Subject must be at most 80 Years

Eligibility (NLI label): Entailment